Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib Induction Before Radiotherapy and Maintenance in Stage III NSCLC
NCT07295821Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2026
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Progression-Free Survival up to 2 years. Started Apr 2026; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07295821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07295821.